As previously reported, the Federal Court dismissed Apotex’s application for judicial review of the decision of the Therapeutic Products Directorate (TPD), which continued to require Apotex to submit additional information with respect to products manufactured or tested in Apotex’s facilities in India. On August 2, 2018, the Federal Court of Appeal dismissed Apotex’s appeal: Apotex Inc v Canada (Health), 2018 FCA 147. The Federal Court of Appeal found that the application judge made no reviewable error in finding that the TPD’s decision was not improperly motivated, and dismissed the appeal.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More -
2025 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.Read More